SLS 241220 1.00P (SLS241220P1000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

SLS241220P1000

Watchlist

0.07
0.000.00%

15min DelayTrading Dec 20 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 Am ET
GlobeNewswireJan 2 08:00 ET
Promising Phase 2 Results and Strategic Potential Drive Buy Rating for SELLAS Life Sciences' SLS009
TipRanksDec 11, 2024 08:05 ET · Ratings
Express News | Sellas Life Sciences Group: Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating Interim Analysis
ReutersDec 10, 2024 08:33 ET
Express News | Sellas Life Sciences Group: Regal Independent Data Monitoring Committee to Perform Interim Analysis in Jan 2025
ReutersDec 10, 2024 08:31 ET
Express News | Sellas Life Sciences Triggers Interim Analysis in Phase 3 Regal Trial of Gps in Acute Myeloid Leukemia
ReutersDec 10, 2024 08:31 ET
SELLAS Reports Positive Survival Data From Mid-stage Trial of Its Leukemia Treatment
Seeking AlphaDec 9, 2024 09:28 ET

Comments

Jaguar8

Dec 10, 2024 07:57

NEWS

$Sellas Life Sciences (SLS.US)$
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
Tuesday, 10th December at 8:30 am
- Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis –
- REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 -
- Company to Host Webcast Call Today at 9:00 am ET
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: ...

Trytosaveabit

Dec 9, 2024 07:47

Update

$Sellas Life Sciences (SLS.US)$ SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
2 MINUTES AGO, 8:45 AM EST
VIA GLOBENEWSWIRE
Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens -
- Overall Response Rate (ORR) of 56% Achieved to Date in Patient with Acute Myeloid Leukemia with Myelodysplasia Relat...

Jaguar8

Dec 9, 2024 07:45

NEWS

$Sellas Life Sciences (SLS.US)$
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
Monday, 9th December at 8:45 am
- Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens -
- Overall Response Rate (ORR) of 56% Achieved to Date in Patient with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AM...

Jaguar8

Dec 8, 2024 16:31

SLS presenting in ASH Conference

$Sellas Life Sciences (SLS.US)$
“SELLAS Life Sciences To Present Phase 2a Data On SLS009 For Relapsed/Refractory AML At ASH 2024, Showing 50% Response Rate And Median OS Of 5.5 Months At Selected Doses”

Trytosaveabit

Nov 27, 2024 07:50

Update

$Sellas Life Sciences (SLS.US)$ Reuters· 2 mins ago
Sellas: Asxl1 Mutations Predictably Identified in Colorectal Cancer and Non-Small Cell Lung Cancer in Addition to Hematologic Malignancies